Citicoline
Citicoline (CDP-Choline)
A brain-boosting compound that enhances memory, focus, and mental energy by supporting acetylcholine and phospholipid synthesis.
Citicoline (CDP-choline) is a naturally occurring compound that serves as a precursor to both acetylcholine (a key neurotransmitter for memory and learning) and phosphatidylcholine (a major component of brain cell membranes). It has shown benefits for cognitive function and is used clinically in some countries for stroke recovery.
Mechanisms of Action
Acetylcholine Synthesis
Provides choline for neurotransmitter production
Membrane Repair
Supports brain cell membrane structure
Dopamine Support
May increase dopamine receptor density
Recommended Dose
250-500mg daily
Optimal Timing
- Morning for daytime cognitive enhancement
Can be taken without food
Best Form
Cognizin® branded citicoline
Alternatives: Generic citicoline, CDP-choline
Cognizin is the most-studied branded form. Quality can vary with generic versions.
Duration
Minimum: 4 weeks
Optimal: 8 weeks
Cycling: Not required
Note: Can be taken with or without food. Morning dosing preferred for focus benefits. Some split dose AM/PM.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Sharper Focus
Better attention and concentration
Improved Memory
Enhanced learning and recall
Mental Clarity
Clearer thinking and reduced brain fog
Limited safety data; consult healthcare provider
Well-studied in older adults; may be particularly beneficial
Who Should NOT Take This
- None known at recommended doses
Drug Interactions
May counteract anticholinergic effects
Additive cholinergic effects
Possible Side Effects
Tip: Reduce dose
Tip: Take earlier in day
Tip: Take with food
Warnings
- Very well tolerated
- May cause insomnia if taken too late
- Effects are subtle but cumulative
Omega-3
complementaryBoth support brain structure and function
Comprehensive brain health support
Bacopa Monnieri
stacks-wellDifferent mechanisms for cognitive enhancement
Enhanced memory and focus from multiple angles
Alpha-GPC
complementaryDifferent choline sources with complementary effects
Enhanced acetylcholine and membrane support
Top studies from 40+ peer-reviewed papers
Martí-Carvajal AJ et al. • The Cochrane database of systematic reviews (2020)
“This review assessed the clinical benefits and harms of citicoline compared with placebo or any other standard treatment for people with acute ischemic stroke.”
Key Findings:
- A pooled analysis of eight trials indicates there may be little or no difference in all-cause mortality comparing citicoline with placebo (17.3% versus 18.5%; RR 0.94, 95% CI 0.83 to 1.07; I² = 0%; low-quality evidence due to risk of bias).
- Four trials found no difference in the proportion of patients with disability or dependence in daily activities according to the Rankin scale comparing citicoline with placebo (21.72% versus 19.23%; RR 1.11, 95% CI 0.97 to 1.26; I² = 1%; low-quality evidence due to risk of bias).
- Meta-analysis of three trials indicates there may be little or no difference in serious cardiovascular adverse events comparing citicoline with placebo (8.83% versus 7.77%; RR 1.04, 95% CI 0.84 to 1.29; I² = 0%; low-quality evidence due to risk of bias).
- Four trials assessing functional recovery with the Barthel Index at a cut-off point of 95 points or more did not find differences comparing citicoline with placebo (32.78% versus 30.70%; RR 1.03, 95% CI 0.94 to 1.13; I² = 24%; low-quality evidence due to risk of bias).
Shi PY et al. • Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban (2016)
“In conclusion, citicolne cannot reduce long-term mortality and dependence rate in the treatment of acute stroke, and the effective rate of citivoline may be not better than that of controls but with reliable safety.”
Key Findings:
- The overall rate of adverse events in citicoline group was not significantly different from that in control group (P=0.30).
- The quality of included articles reached moderate-low level.
- In conclusion, citicolne cannot reduce long-term mortality and dependence rate in the treatment of acute stroke, and the effective rate of citivoline may be not better than that of controls but with reliable safety.
Kruoch Z et al. • The Cochrane database of systematic reviews (2025)
“Neurotrophic keratopathy is a rare condition with an array of etiologies, which poses challenges for research in terms of study design, participant recruitment, and consensus on objective outcome measures.”
Key Findings:
- Meta-analysis of two studies showed that rhNGF may slightly improve corneal re-epithelialization (defined as < 0.5 mm of corneal staining) (RR 1.88, 95% CI 1.37 to 2.58; I2 = 0%; 148 participants; low-certainty evidence).
- The same two studies assessed complete corneal re-epithelialization (defined as < 0.1 mm of corneal staining) and found similar results but with substantial heterogeneity in the meta-analysis (RR 2.75, 95% CI 1.82 to 4.16; I2 = 72%; 148 participants; low-certainty evidence).
- Meta-analysis of two studies showed that rhNGF may not improve visual acuity (RR 0.07, 95% CI -0.58 to 0.71; I2 = 0%; 151 participants; low-certainty evidence).
- Meta-analysis of two studies suggested that medical interventions, specifically rb-bFGF, may improve corneal sensitivity (MD 8.43, 95% CI 1.90 to 14.97; I2 = 0%; 60 participants; very low-certainty evidence), but the evidence is very uncertain.
Bonvicini M et al. • Nutrients (2023)
“The overall quality of the studies was poor.”
Key Findings:
- Overall, citicoline improved cognitive status, with pooled standardized mean differences ranging from 0.56 (95% CI: 0.37-0.75) to 1.57 (95% CI: 0.77-2.37) in different sensitivity analyses.
- Published in Nutrients (2023)
- Further research warranted to confirm findings
Dean RL et al. • The Cochrane database of systematic reviews (2021)
“Our findings show that ketamine and esketamine may be more efficacious than placebo at 24 hours.”
Key Findings:
- The evidence suggests that ketamine may result in an increase in response and remission compared with placebo at 24 hours odds ratio (OR) 3.94, 95% confidence interval (CI) 1.54 to 10.10; n = 185, studies = 7, very low-certainty evidence).
- Ketamine may reduce depression rating scale scores over placebo at 24 hours, but the evidence is very uncertain (standardised mean difference (SMD) -0.87, 95% CI -1.26 to -0.48; n = 231, studies = 8, very low-certainty evidence).
- There was no difference in the number of participants assigned to ketamine or placebo who dropped out for any reason (OR 1.25, 95% CI 0.19 to 8.28; n = 201, studies = 6, very low-certainty evidence).
- When compared with midazolam, the evidence showed that ketamine increases remission rates at 24 hours (OR 2.21, 95% CI 0.67 to 7.32; n = 122,studies = 2, low-certainty evidence).
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.